The Motley Fool

Is the GSK share price a bargain at £14.35?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope
Image: GlaxoSmithKline

The GlaxoSmithKline (LSE: GSK) share price was £14.23 when I last wrote about the company three weeks ago. This was shortly before management issued an investor update on 23 June. The update was all about ‘New GSK’ — after the planned demerger of the consumer healthcare business — and a new dividend policy.

My pre-update article was titled Why I’d buy GSK shares despite the coming dividend cut. Having now read and digested the company’s plans and new dividend policy, and with the shares up a whopping (not!) 0.8% to £14.35, am I still keen on the stock today?

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Dividend outlook

In the investor update, GSK reiterated its previously stated intention to pay a dividend of 80p per share for 2021. This had been the annual payout going back to when Roy Hodgson was manager of the England football team!

The company had also previously said that for 2022 it expected the aggregate dividend of New GSK and New Consumer Healthcare to be less than 80p. It hadn’t put an exact figure on it, but the analyst consensus was 54.6p. This turned out to be pretty much bang on the money. In the investor update, management said it expects the 2022 aggregate dividend to be 55p.

At the current GSK share price, the 2021 80p dividend represents a yield of 5.6%. The 31% reduction to 55p in 2022 brings it down to 3.8%. The company also told us that New GSK will have a progressive dividend policy starting at 45p (3.1% yield) in 2023. There’ll be the New Consumer Healthcare dividend too, but this will be down to its new board of directors.

The dividend outlook is in line with what I expected. As such, the payout prospects don’t negatively impact my previous positive view of the stock.

GSK share price prospects

I think GSK’s reduced, but more sustainable and progressive, dividend makes the company a better investment proposition. The rebasing of distributions to shareholders will allow management to increase New GSK’s R&D and commercial investment in vaccines and speciality medicines. This should underpin long-term sales and profit growth. And in turn, the progressive dividend.

Aside from the better balance between shareholder distributions and investment for growth, I felt the demerger of the consumer healthcare business could unlock value for shareholders. Due to what I think is a current ‘conglomerate discount’, I reckon the two businesses will be valued more highly by the market as standalone companies. This could provide an added boost to GSK’s share price.

Nothing in the investor update has changed my view that the separation will ultimately unlock value for shareholders and that the standalone businesses can thrive with energised and focused management.

On the subject of management, GSK’s board “strongly believes” current CEO Emma Walmsley is the right leader for New GSK. However, given her background and experience in the group’s consumer healthcare business — and before that 17 years with personal care company L’Oréal — there’s an argument she may not be the most  effective leader of a business focused on new vaccines and speciality medicines.

Despite this risk, and the risk around delivering the demerger successfully, I continue to like GSK. It may not quite be the bargain of the century, but I think it’s a very buyable stock for my portfolio at the current share price.

Our 5 Top Shares for the New “Green Industrial Revolution"

It was released in November 2020, and make no mistake:

It’s happening.

The UK Government’s 10-point plan for a new “Green Industrial Revolution.”

PriceWaterhouse Coopers believes this trend will cost £400billion…

…That’s just here in Britain over the next 10 years.

Worldwide, the Green Industrial Revolution could be worth TRILLIONS.

It’s why I’m urging all investors to read this special presentation carefully, and learn how you can uncover the 5 companies that we believe are poised to profit from this gargantuan trend ahead!

Access this special "Green Industrial Revolution" presentation now

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.